Navigation Links
Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
Date:6/3/2008

CRANBURY, N.J., June 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has initiated a Phase 2 clinical trial of AT2220 (1-deoxynojirimycin HCl), for the treatment of Pompe disease. Amicus will conduct the study in adult Pompe patients in clinical centers throughout North America and Europe. AT2220 is the third compound based on Amicus' pharmacological chaperone technology platform to enter Phase 2 clinical development.

"We look forward to evaluating AT2220 as a potential new oral therapeutic option for patients living with Pompe disease," said Barry J. Byrne, M.D., Ph.D., professor of pediatrics, molecular genetics and microbiology at the University of Florida in Gainesville and an investigator in the Phase 2 trial.

AT2220 is designed to selectively bind to, stabilize and elevate the cellular activity of acid alpha-glucosidase (GAA), the enzyme deficient in Pompe disease. This deficiency leads to lysosomal accumulation of glycogen inside cells, which is believed to cause the various symptoms of Pompe disease.

Amicus is initiating the multi-national, open-label Phase 2 clinical trial designed to enroll 18 adult patients diagnosed with Pompe disease. The primary objective of the study is to evaluate the safety and tolerability of different dosing regimens of AT2220 over a 12-week period. The study will also explore certain pharmacodynamic and pharmacokinetic measures including the effect of treatment with AT2220 on GAA activity and on glycogen levels in various cells and tissues. Additional objectives include preliminary assessments of p
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Today the US Surgeon General issued the ... tanning or sun burns stating they can lead directly to ... Boris Lushniak , says that "skin cancer is a major ... much exposure to indoor and outdoor ultraviolet light is a ... Medicine, in Boca Raton, Florida , ...
(Date:7/30/2014)... Reportlinker.com announces that a new market ... mHealth and Home Monitoring – 6th Edition ... Executive summary mHealth can revolutionize how ... decreased costs and improved sustainability of the healthcare ... in an early stage, but on the brink ...
(Date:7/30/2014)... N.J. , July 30, 2014 Stryker brand ambassadors ... this week at the 3M Championship Champions Tour event near ... Cities, in Blaine . Stryker is the official ... Starting Friday, August 1 st through Sunday, ... Stryker Mobility Zone; an on-site joint health destination located in the ...
Breaking Medicine Technology:Indoor and Outdoor Sun Tanning or Sun Burns Directly Linked to Deadly Melanoma Skin Cancer 2mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5
... Masimo (NASDAQ: MASI ) announced today ... for the period ended December 31, 2011, after the market closes ... will begin at 1:30 p.m. PT (4:30 p.m. ET) and will ... Mark P. de Raad, Executive Vice President and Chief Financial Officer. ...
... NEW YORK, Jan. 26, 2012 Dr. Ira J. Haimowitz, ... CementBloc, will be a featured presenter at the eMarketing University ... New York City on February 6, 2012. The ... product management seeking to incorporate digital tactics into their marketing ...
Cached Medicine Technology:Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 2Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 3Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™ 2
(Date:7/31/2014)... Nashville, TN (PRWEB) July 31, 2014 ... a pipeline partner with the National Rural Health Association ... commitment by ProtonPACS to understanding the needs of rural ... with the National Rural Health Association,” said Dr. Mark ... share the many advantages of ProtonPACS, we are also ...
(Date:7/31/2014)... 2014) While it is known that members of the ... a new study finds that female enlistees and female ... civilian counterparts. This study was published today in ... on behalf of the Inter-University Seminar on Armed Forces ... Tedrow studied surveys of nearly 9,000 men and women ...
(Date:7/31/2014)... Staying happy in a relationship and loving for years ... get sucked into the logistical ruts they know as their ... kids. , That’s why Couples in Trouble Relationship Expert, ... to Reignite the Spark in Your Marriage TODAY” Guide as ... much better path to happiness, and a far less costly ...
(Date:7/31/2014)... According to new research report "Meat Substitutes ... (Tofu, Tofu-Based Product, Tempeh, TVP, Seitan, Quorn, Others), ... Forecasts to 2019", defines and segments the global ... of the market value of sources, types, and ... the driving and restraining factors for the global ...
(Date:7/31/2014)... Eden Lew has been awarded the ... Technologies" Scholarship through EDSF (Electronic Document ... the contributions Chuck Forman made throughout his career ... his battle with cancer on October 2, 2013. ... thrilled to see her receive the second annual ...
Breaking Medicine News(10 mins):Health News:ProtonPACS Announces Pipeline Partnership with the National Rural Health Association. 2Health News:Women in military less likely to drink than civilian women 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 2Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 3
... Consumer protection group,s new resource helps Americans cut prescription ... , WASHINGTON, Dec. 1 A collection ... to consumers to help fend off the dangers of ... Partnership for Safe Medicines, "Consumer Resources" is designed to ...
... Indicated for the Treatment of Both Moderate to Severe Vaginal Dryness ... Due to Menopause , , ... , MONTVALE, N.J., Dec. 1 Barr ... U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed ...
... found in disorder, study says , , MONDAY, Dec. ... process sounds a fraction of a second slower than ... and language issues linked to the condition, a new ... which records minute magnetic fields associated with electrical brain ...
... lesson from 2 failed trials: The science must be more vigorous, ... HIV would give up without a fight. , As World AIDS ... at what went wrong in recent, high-profile failures of two human ... is still very possible, and with it comes the ...
... Decision Resources, one of the,world,s leading research and advisory ... share for GlaxoSmithKline,s Advair is,declining in all lines of ... The new report entitled Treatment ... first-, second- and third-lines of therapy to 12.2 percent,13.6 ...
... the international generic pharmaceuticals company, today announced that it ... Administration to market Bupropion Hydrochloride extended-release tablets (XL) 150mg. ... , , Bupropion Hydrochloride ... are the generic equivalent of Wellbutrin XL(R) for the ...
Cached Medicine News:Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 2Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 3Health News:Partnership for Safe Medicines Arms Public Against Counterfeit Drugs 4Health News:FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream 2Health News:FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream 3Health News:FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream 4Health News:FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream 5Health News:FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream 6Health News:FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream 7Health News:Scans Show Sound-Processing Deficits in Autistic Kids 2Health News:Hopes for AIDS Vaccine Still Alive Despite Setbacks 2Health News:Hopes for AIDS Vaccine Still Alive Despite Setbacks 3Health News:Hopes for AIDS Vaccine Still Alive Despite Setbacks 4Health News:Advair's Patient Share in Newly Diagnosed Asthma Patients is Declining 2Health News:Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S. 2
The Prostar XL 8 is a suture mediated closure system. It can be used with 8F sheath. It has two 3-0 braided polyester sutures and also has the safety of guidewire....
... vascular closure device quickly seals ... procedures, allowing for early ambulation ... creates a mechanical seal by ... bio-absorbable anchor and collagen sponge, ...
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: